European Commission clears Johnson and Johnson's acquisition of DePuy
This article was originally published in Clinica
The European Commission has told Johnson & Johnson that it can buy orthopaedics company DePuy. A question mark was held over the deal last month when the Commission decided it needed further information before reaching a decision (see Clinica No 831, p 9).
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.